Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,271.76 -35.25 (-0.66%) Dow
39,098.89 -572.15 (-1.44%) Nasdaq
16,749.11 -52.44 (-0.31%) Bitcoin USD
67,365.91 -2,246.30 (-3.23%) CMC Crypto 200
1,469.01 -33.65 (-2.24%)
Scilex Holding Company (SCLX)
- Simply Wall St.
With Scilex Holding Up 36%, Insider Buyers Count Their Returns
Insiders who bought Scilex Holding Company ( NASDAQ:SCLX ) stock in the last 12 months were richly rewarded last week...
- GlobeNewswire
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the 45-day review period for the U.S. Federal Trade Commission and U.S. Department of Justice to comment on or object to the Settlement Agreement (the “Settlement Agreement”) entered into by
- GlobeNewswire
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
Scilex management is determined to enhance its stockholders’ value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Of the approximately 181 million shares of Scilex common stock currently issued and outstanding: (a) 76 million were distributed by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) as dividend shares in January 2023 (the “Dividend Shares”) and are restricted from trading until the earlier o
